Department of Neurology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China (mainland).
Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Gannan Medical University, Ganzhou, Jiangxi, China (mainland).
Med Sci Monit. 2019 Jan 22;25:637-642. doi: 10.12659/MSM.913977.
BACKGROUND Worldwide, stroke results in healthcare costs and economic costs, particularly in patients aged <45 years. This study aimed to evaluate the factors influencing the economic burden of ischemic stroke in younger patients in China based on the Trial of Org 10172 in Acute Stroke Treatment (TOAST) etiological classification. MATERIAL AND METHODS Retrospective review of the medical records of 961 patients aged between 18-45 years, diagnosed with acute ischemic stroke, was performed to identify healthcare costs for one year. Stroke severity was assessed using the modified Rankin Scale (mRS) score and the National Institutes of Health Stroke Scale (NIHSS) score. Stroke was categorized according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification as being due to large artery atherosclerosis (LAA), cardioembolism (CE), small artery occlusion (SAO), other determined causes (OC), and undetermined etiology (UND). RESULTS Total direct medical costs at one-year follow-up were US$10,954.14, including inpatient cost of US$5,958.44, and outpatient cost of US$3,397.60. Inpatient and total costs at one year were significantly increased in the CE subtype (P<0.001), and were significantly less in the UND subtype (P<0.001). Multivariable logistic regression analysis showed that mRS score, TOAST category, NIHSS score, and the presence of atrial fibrillation were the significant factors influencing cost at one-year follow-up and total cost in younger patients with ischemic stroke. Overall, patient costs in China were less than those in high-income countries. CONCLUSIONS In the younger patient population in China, etiological factors influenced the economic burden of ischemic stroke.
在全球范围内,卒中导致医疗保健成本和经济成本增加,尤其是在 <45 岁的患者中。本研究旨在根据试验性组织纤溶酶原激活剂治疗急性卒中(TOAST)病因分类,评估影响中国年轻患者缺血性卒中经济负担的因素。
回顾性分析了 961 例年龄在 18-45 岁之间、诊断为急性缺血性卒中的患者的病历,以确定一年内的医疗保健费用。使用改良 Rankin 量表(mRS)评分和美国国立卫生研究院卒中量表(NIHSS)评分评估卒中严重程度。根据试验性组织纤溶酶原激活剂治疗急性卒中(TOAST)分类,将卒中分为大动脉粥样硬化(LAA)、心源性栓塞(CE)、小动脉闭塞(SAO)、其他明确原因(OC)和不明原因(UND)。
一年随访时的总直接医疗费用为 10954.14 美元,其中住院费用为 5958.44 美元,门诊费用为 3397.60 美元。CE 亚型的住院和总费用在一年时显著增加(P<0.001),UND 亚型的住院和总费用显著降低(P<0.001)。多变量逻辑回归分析表明,mRS 评分、TOAST 分类、NIHSS 评分和心房颤动的存在是影响年轻缺血性卒中患者一年随访时成本和总费用的显著因素。总的来说,中国患者的费用低于高收入国家。
在中国年轻患者人群中,病因因素影响了缺血性卒中的经济负担。